✦ LIBER ✦

P.19 Docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer (NSCLC): a preliminary report of a randomized phase III trial

✍ Scribed by Karampeazis, A.; Vamvakas, L.; Tsiafaki, X.; Kalykaki, A.; Christophyllakis, Ch.; Bozionelou, V.; Gkioulbasanis, J.; Markos, V.; Giannousi, Z.; Androulakis, N.

Book ID: 123281867
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 71 KB
Volume: 64
Category: Article
ISSN: 1040-8428
DOI: 10.1016/S1040-8428(13)70192-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Management of chemotherapy in elderly pa

Management of chemotherapy in elderly patients with advanced non small cell lung cancer (NSCLC): A phase III randomized trial

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 167 KB

116 Phase III trial of docetaxel plus vi

116 Phase III trial of docetaxel plus vinorelbine in patients with advanced non-small cell lung cancer

✍ Kris, M.G.; Miller, V.A.; Grant, S.C.; Pizzo, B.A.; Early, E.; Martino, D.; Heel 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Docetaxel Vs. Vinorelbine in Elderly Pat

Docetaxel Vs. Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: A Hellenic Oncology Research Group Randomized Phase III Study

✍ Athanasios Karampeazis; Lambros Vamvakas; Athina Agelidou; Nikolaos Kentepozidis 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 347 KB

Docetaxel Versus Docetaxel/Cisplatin in

Docetaxel Versus Docetaxel/Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Analysis of a Multicenter, Randomized Phase III Study

✍ V. Georgoulias; A.G. Pallis; C. Kourousis; A. Alexopoulos; A. Ardavanis; A. Agel 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 150 KB

1070 Phase II trial with docetaxel in pa

1070 Phase II trial with docetaxel in patients (PTS) with non small cell lung cancer (NSCLC)

✍ Latreille, J.; Laberge, F.; Viallet, J.; Maksymiuk, A.; Shepherd, F.; Gelmon, K. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 163 KB

9001 Vandetanib plus docetaxel versus do

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Eberhardt, W.E.E.; Johnson, B.E.; Sun, Y.; Germonpré, P.; Saijo, N.; Zhou, C.; W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB